Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials and Head of the Cancer Program for the Faculty of Medicine and Health Sciences at Macquarie University and Senior Staff Specialist in Medical Oncology at Westmead Hospital.
Dr Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 150 clinical trials and has over 150 per-reviewed publications in genitourinary cancers and pharmacogenomics, including recent papers in the New Engl J Med, Lancet and Lancet Oncology. Current research interests also include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as an authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint
Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
CTU: A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy
Gurney, H. (Primary Chief Investigator), Martin, L. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff), Chapman, N. (Clinical Trial Unit Staff) & Armstrong, E. (Clinical Trial Unit Staff)
6/02/25 → 27/11/29
Project: Research
-
CTU A Phase 2, Open-Label, Multicentre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Gurney, H. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff), Armstrong, E. (Clinical Trial Unit Staff), McHugh, T. (Clinical Trial Unit Staff) & Garcia, M. (Clinical Trial Unit Staff)
8/10/24 → 29/05/29
Project: Research
-
CTU: A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy in participants with clear cell renal cell carcinoma and other solid tumors.
Gurney, H. (Primary Chief Investigator), Martin, L. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff) & Chapman, N. (Clinical Trial Unit Staff)
14/07/24 → 29/05/29
Project: Research
-
V940-004: CTU: A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants with Renal Cell Carcinoma
Gurney, H. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff) & Chester, C. (Clinical Trial Unit Staff)
8/03/24 → 27/09/28
Project: Research
-
The ACRF Centre for Advanced Cancer Modelling and Experimental Oncology (COMET)
Rizos, H. (Primary Chief Investigator), Gurney, H. (Chief Investigator), Shklovskaya, E. (Chief Investigator), Long, G. V. (Chief Investigator), Lee, J. (Chief Investigator), Wang, Y. (Chief Investigator), Di Ieva, A. (Chief Investigator), Guller, A. (Chief Investigator), Clarke AM, J. (Chief Investigator) & Gupta, R. (Chief Investigator)
1/01/24 → 31/12/30
Project: Research
-
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
Menzies, A. M., Salman, P., Frontera, O. A., Pook, D., Hocking, C. M., Zakharia, Y., Gurney, H., Gedye, C., Goh, J. C., Telivala, B., Grob, J. J., Lebbé, C., de la Cruz Merino, L., Machet, L., Neidhardt, E. M., Qureshi, A., Hosein, F., Hamuro, L., Simsek, B. & Amin, A., 15 Jul 2025, In: Cancer. 131, 14, p. 1-11 11 p., e35962.Research output: Contribution to journal › Article › peer-review
Open AccessFile8 Downloads (Pure) -
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
Choueiri, T. K., Penkov, K., Uemura, H., Campbell, M. T., Pal, S., Kollmannsberger, C., Lee, J. L., Venugopal, B., van den Eertwegh, A. J. M., Negrier, S., Gurney, H., Albiges, L., Berger, R., Haanen, J. B. A. G., Oyervides Juárez, V., Rini, B. I., Larkin, J., Nolè, F., Schmidinger, M. & Atkins, M. B. & 7 others, , Apr 2025, In: Annals of Oncology. 36, 4, p. 387-392 6 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile8 Citations (Scopus)8 Downloads (Pure) -
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with nonvisceral or lymph node–only disease
Bellmunt, J., Powles, T., Park, S. H., Voog, E., Valderrama, B. P., Gurney, H., Ullén, A., Loriot, Y., Sridhar, S. S., Tsuchiya, N., Sternberg, C. N., Aragon-Ching, J. B., Petrylak, D. P., Climent Duran, M. A., Tyroller, K., Hoffman, J., Jacob, N., Grivas, P. & Gupta, S., Oct 2025, In: European Urology. 88, 4, p. 331-338 8 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus) -
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
Gupta, S., Climent Duran, M. A., Sridhar, S. S., Powles, T., Bellmunt, J., Park, S. H., Gurney, H., Tsuchiya, N., Petrylak, D. P., Tomita, Y., di Pietro, A., Manitz, J., Tyroller, K., Hoffman, J., Jacob, N. & Grivas, P., Apr 2025, In: ESMO Open. 10, 4, p. 1-9 9 p., 104506.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)2 Downloads (Pure) -
Avelumab maintenance treatment for advanced urothelial cancer: plain language summary of long-term results from the JAVELIN Bladder 100 study
Powles, T., Park, S. H., Gurney, H., Loriot, Y., Sridhar, S. S., Bellmunt, J., di Pietro, A. & Grivas, P., 7 Feb 2025, In: Future Oncology. 21, 4, p. 381-391 11 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile9 Downloads (Pure)